David Nierengarten Analyst PerformanceManaging Director, Equity Research at WedbushDavid Nierengarten is a stock analyst at Wedbush in the healthcare sector, covering 39 publicly traded companies. Over the past year, David Nierengarten has issued 118 stock ratings, including buy and hold recommendations. While full access to David Nierengarten's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Nierengarten's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings169 Last 11 YearsBuy Recommendations82.04% 137 Buy RatingsCompanies Covered39 Unique Companies Ratings Distribution167RatingsDistribution of strong buy, buy, hold, and sell ratings by David Nierengarten.RatingPercentageCount Strong Buy0.0%0 ratings Buy82.0%137 ratings Hold18.0%30 ratings Sell0.0%0 ratingsOut of 167 total stock ratings issued by David Nierengarten at Wedbush, the majority (82.0%) have been Buy recommendations, followed by 18.0% Hold.Best & Worst CallsBest Call0000.0%STTKSep 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%DAREApr 2016Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ94.9% of companies on NASDAQ37 companiesNYSE2.6% of companies on NYSE1 companyNYSEAMERICAN2.6% of companies on NYSEAMERICAN1 companyDavid Nierengarten, an analyst at Wedbush, currently covers 39 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare39 companies100.0%David Nierengarten of Wedbush specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY34 companies87.2%PHARMACEUTICALS4 companies10.3%HEALTHCARE EQUIPMENT & SUPPLIES1 company2.6% About David NierengartenDavid Nierengarten, Ph.D., has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy. His prior experience in venture capital and operations at a private biotechnology company, helps him succeed in analyzing both science and business models. In addition, David has results in predicting Dendreon’s looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor. David received his B.S. in Biochemistry from the University of Wisconsin-Madison, and Ph.D. in Molecular and Cell Biology from the University of California at Berkeley. David Nierengarten's Ratings History at Wedbush Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsAKTSAktis Oncology10/2/2026Reiterated Rating$18.38$35.00Outperform$0.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock9/29/2026Reiterated Rating$20.75$40.00Outperform$0.0000.00% ROITLXTelix Pharmaceuticals9/23/2026Reiterated Rating$11.95$22.00Outperform$0.0000.00% ROIABVXAbivax9/22/2026Lower Price Target$103.45$118.00Neutral$0.0000.00% ROINUVBNuvation Bio9/16/2026Reiterated Rating$5.80$11.00Outperform$0.0000.00% ROICOGTCogent Biosciences9/16/2026Reiterated Rating$32.74$55.00Outperform$0.0000.00% ROISRRKScholar Rock9/15/2026Reiterated Rating$47.39$64.00Outperform$0.0000.00% ROICATXPerspective Therapeutics9/15/2026Reiterated Rating$2.77$11.00Outperform$0.0000.00% ROISRRKScholar Rock9/14/2026Reiterated Rating$55.41$64.00Outperform$0.0000.00% ROITLXTelix Pharmaceuticals9/14/2026Reiterated Rating$11.29$22.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. IRONDisc Medicine9/10/2026Reiterated Rating$76.51$100.00Outperform$0.0000.00% ROIBBOTBridgeBio Oncology Therapeutics9/9/2026Reiterated Rating$8.86$25.00Outperform$0.0000.00% ROINTLAIntellia Therapeutics9/9/2026Boost Price Target$12.74$13.00Neutral$0.0000.00% ROISYRESpyre Therapeutics9/9/2026Reiterated Rating$90.79$123.00Outperform$0.0000.00% ROIBEAMBeam Therapeutics9/9/2026Reiterated Rating$26.83$65.00Outperform$0.0000.00% ROIARGXargenex9/3/2026Reiterated Rating$1,055.37$1,150.00Outperform$0.0000.00% ROITCRXTScan Therapeutics9/2/2026Downgrade$0.42$1.00Neutral$0.0000.00% ROIIRONDisc Medicine9/2/2026Boost Price Target$78.67$100.00Outperform$0.0000.00% ROISYRESpyre Therapeutics8/26/2026Lower Price Target$107.36$123.00Outperform$0.0000.00% ROISRRKScholar Rock8/21/2026Reiterated Rating$56.41$64.00Outperform$0.0000.00% ROITLXTelix Pharmaceuticals8/20/2026Reiterated Rating$12.30$22.00Outperform$0.0000.00% ROIAKTSAktis Oncology8/19/2026Initiated Coverage$25.00$35.00Outperform$0.0000.00% ROIARGXargenex8/18/2026Boost Price Target$987.84$1,150.00Outperform$0.0000.00% ROISTROSutro Biopharma8/13/2026Reiterated Rating$21.30$60.00Outperform$0.0000.00% ROIIMNMImmunome8/12/2026Boost Price Target$26.05$35.00Outperform$0.0000.00% ROICOAGHemab Therapeutics8/12/2026Boost Price Target$51.04$64.00Outperform$0.0000.00% ROIBCAXBicara Therapeutics8/12/2026Boost Price Target$23.76$33.00Outperform$0.0000.00% ROIFENCAdherex Technologies8/12/2026Boost Price Target$12.19$16.00Outperform$0.0000.00% ROISRRKScholar Rock8/10/2026Reiterated Rating$51.45$58.00Outperform$0.0000.00% ROIXNCRXencor8/6/2026Boost Price Target$19.10$30.00Outperform$0.0000.00% ROISYRESpyre Therapeutics8/5/2026Boost Price Target$103.85$130.00Outperform$0.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock7/30/2026Boost Price Target$28.99$40.00Outperform$0.0000.00% ROIXNCRXencor7/30/2026Reiterated Rating$19.86$26.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International7/29/2026Boost Price Target$79.83$99.00Outperform$0.0000.00% ROIARGXargenex7/28/2026Boost Price Target$888.82$1,050.00Outperform$0.0000.00% ROINVCRNovoCure7/24/2026Boost Price Target$19.99$20.00Neutral$0.0000.00% ROINUVBNuvation Bio7/23/2026Reiterated Rating$6.51$11.00Outperform$0.0000.00% ROIIMNMImmunome7/21/2026Reiterated Rating$22.22$31.00Outperform$0.0000.00% ROISRRKScholar Rock7/21/2026Reiterated Rating$50.78$58.00Outperform$0.0000.00% ROICOAGHemab Therapeutics7/13/2026Reiterated Rating$38.03$55.00Outperform$0.0000.00% ROIThey're not buying gold. They're buying this. (Ad)Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, and Millennium by 122%. Kopernik Global made it their largest holding, owning roughly 8% of the company. It holds rights to an 88 million ounce deposit with existing roads, power, and permits that never expire. Market cap sits near $4 billion against a deposit worth hundreds of billions at current gold prices.See the name, ticker, and full file nowNTLAIntellia Therapeutics7/10/2026Boost Price Target$15.44$17.00Neutral$0.0000.00% ROITLXTelix Pharmaceuticals7/6/2026Reiterated Rating$11.87$22.00Outperform$0.0000.00% ROIABVXAbivax6/30/2026Boost Price Target$96.15$110.00Neutral$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International6/29/2026Boost Price Target$59.96$72.00Outperform$0.0000.00% ROITCRXTScan Therapeutics6/23/2026Reiterated Rating$0.87$5.00Outperform$0.0000.00% ROIAPGEApogee Therapeutics6/22/2026Downgrade$132.61$135.00Neutral$0.0000.00% ROISYRESpyre Therapeutics6/16/2026Reiterated Rating$81.95$100.00Outperform$0.0000.00% ROINTLAIntellia Therapeutics6/15/2026Reiterated Rating$13.39$12.00Neutral$0.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock6/12/2026Reiterated Rating$21.51$35.00Outperform$0.0000.00% ROIIMNMImmunome6/12/2026Reiterated Rating$18.76$31.00Outperform$0.0000.00% ROIARGXargenex6/11/2026Reiterated Rating$882.46$1,000.00Outperform$0.0000.00% ROIIRONDisc Medicine6/10/2026Reiterated Rating$69.99$88.00Outperform$0.0000.00% ROINUVLNuvalent6/9/2026Downgrade$122.87$124.00Neutral$0.0000.00% ROIARGXargenex6/4/2026Reiterated Rating$813.14$1,000.00Outperform$0.0000.00% ROIABVXAbivax6/2/2026Upgrade$129.69$90.00Neutral$0.0000.00% ROIODTXOdyssey Therapeutics6/2/2026Initiated Coverage$16.96$30.00Outperform$0.0000.00% ROICOGTCogent Biosciences5/29/2026Reiterated Rating$35.21$55.00Outperform$0.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock5/28/2026Initiated Coverage$25.21$35.00Outperform$0.0000.00% ROINUVLNuvalent5/28/2026Reiterated Rating$107.38$125.00Outperform$0.0000.00% ROIAPGEApogee Therapeutics5/27/2026Boost Price Target$84.60$135.00Outperform$0.0000.00% ROICOAGHemab Therapeutics5/26/2026Initiated Coverage$25.89$42.00Outperform$0.0000.00% ROINTLAIntellia Therapeutics5/12/2026Reiterated Rating$14.42$12.00Neutral$0.0000.00% ROISTTKShattuck Labs5/8/2026Boost Price Target$6.48$11.00Outperform$0.0000.00% ROINUVBNuvation Bio5/5/2026Reiterated Rating$4.66$11.00Outperform$0.0000.00% ROICATXPerspective Therapeutics5/5/2026Reiterated Rating$3.78$11.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International4/29/2026Boost Price Target$54.04$59.00Outperform$0.0000.00% ROICATXPerspective Therapeutics4/20/2026Reiterated Rating$4.20$11.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International4/16/2026Boost Price Target$46.31$58.00Outperform$0.0000.00% ROINVCRNovoCure4/16/2026Reiterated Rating$12.24$18.00Neutral$0.0000.00% ROINUVBNuvation Bio4/16/2026Reiterated Rating$4.83$11.00Outperform$0.0000.00% ROIFENCAdherex Technologies4/16/2026Reiterated Rating$6.50$13.00Outperform$0.0000.00% ROISYRESpyre Therapeutics4/13/2026Boost Price Target$64.47$80.00Outperform$0.0000.00% ROITLXTelix Pharmaceuticals4/13/2026Reiterated Rating$10.54$22.00Outperform$0.0000.00% ROINUVLNuvalent4/8/2026Reiterated Rating$102.25$125.00Outperform$0.0000.00% ROITLXTelix Pharmaceuticals4/7/2026Reiterated Rating$9.09$22.00Outperform$0.0000.00% ROINUVBNuvation Bio4/2/2026Reiterated Rating$4.50$11.00Outperform$0.0000.00% ROISRRKScholar Rock4/1/2026Boost Price Target$49.16$58.00Outperform$0.0000.00% ROIORICOric Pharmaceuticals4/1/2026Lower Price Target$12.67$17.00Outperform$0.0000.00% ROIBCAXBicara Therapeutics3/31/2026Reiterated Rating$19.52$30.00Outperform$0.0000.00% ROINUVBNuvation Bio3/27/2026Reiterated Rating$4.41$11.00Outperform$0.0000.00% ROICATXPerspective Therapeutics3/18/2026Reiterated Rating$4.95$11.00Outperform$0.0000.00% ROICOGTCogent Biosciences3/17/2026Reiterated Rating$35.68$55.00Outperform$0.0000.00% ROIARGXargenex3/9/2026Reiterated Rating$717.80$1,000.00Outperform$0.0000.00% ROISTTKShattuck Labs3/6/2026Boost Price Target$5.10$8.00Outperform$0.0000.00% ROITCRXTScan Therapeutics3/5/2026Boost Price Target$1.08$5.00Outperform$0.0000.00% ROIAPGEApogee Therapeutics3/3/2026Boost Price Target$67.77$95.00Outperform$0.0000.00% ROIBEAMBeam Therapeutics2/25/2026Boost Price Target$32.29$65.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International2/25/2026Boost Price Target$43.50$53.00Outperform$0.0000.00% ROIABVXAbivax2/24/2026Initiated Coverage$132.91$110.00Outperform$0.0000.00% ROIORICOric Pharmaceuticals2/24/2026Reiterated Rating$11.71$20.00Outperform$0.0000.00% ROIHow Elon’s Empire Ends (and how to profit) (Ad)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days.See Chaikin's full research and the company name hereIRONDisc Medicine2/17/2026Lower Price Target$55.99$88.00Outperform$0.0000.00% ROINUVBNuvation Bio2/10/2026Reiterated Rating$5.69$11.00Outperform$0.0000.00% ROICATXPerspective Therapeutics1/30/2026Reiterated Rating$4.01$11.00Outperform$0.0000.00% ROICOGTCogent Biosciences1/21/2026Reiterated Rating$39.90$55.00Outperform$0.0000.00% ROIIRONDisc Medicine1/15/2026Reiterated Rating$72.74Outperform$0.0000.00% ROIIMNMImmunome1/15/2026Reiterated Rating$20.76$31.00Outperform$0.0000.00% ROINVCRNovoCure1/15/2026Reiterated Rating$13.77$18.00Neutral$0.0000.00% ROIARGXargenex1/14/2026Reiterated Rating$810.51$1,000.00Outperform$0.0000.00% ROIBCAXBicara Therapeutics1/13/2026Reiterated Rating$17.43$30.00Outperform$0.0000.00% ROIORICOric Pharmaceuticals1/13/2026Reiterated Rating$9.15$20.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International1/13/2026Boost Price Target$41.12$50.00Outperform$0.0000.00% ROIGBIOGeneration Bio12/16/2025Set Price Target$5.39$5.50Outperform$0.0000.00% ROIORICOric Pharmaceuticals12/8/2025Reiterated Rating$11.00$20.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International12/2/2025Reiterated Rating$40.07$48.00Outperform$0.0000.00% ROINUVLNuvalent11/17/2025Reiterated Rating$108.00$125.00Outperform$0.0000.00% ROIARGXargenex11/14/2025Boost Price Target$894.31$1,000.00Outperform$0.0000.00% ROIANABAnaptysBio11/10/2025Reiterated Rating$33.21$50.00Outperform$0.0000.00% ROINTLAIntellia Therapeutics11/7/2025Lower Price Target$9.84$7.00Neutral$0.0000.00% ROIXNCRXencor11/6/2025Reiterated Rating$14.24$26.00Outperform$0.0000.00% ROINTLAIntellia Therapeutics10/30/2025Set Price Target$12.37$9.00$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International10/28/2025Reiterated Rating$40.45$48.00Outperform$0.0000.00% ROIFATEFate Therapeutics10/27/2025Upgrade$1.65$7.00Outperform$0.0000.00% ROIIRONDisc Medicine10/17/2025Boost Price Target$74.36$110.00Outperform$0.0000.00% ROIANABAnaptysBio10/15/2025Boost Price Target$31.85$70.00Outperform$0.0000.00% ROIARGXargenex10/13/2025Boost Price Target$796.92$880.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International10/13/2025Boost Price Target$37.89$44.00Outperform$0.0000.00% ROINUVBNuvation Bio10/13/2025Reiterated Rating$3.73$6.00Outperform$0.0000.00% ROISTTKShattuck Labs9/8/2025Initiated Coverage$1.55$4.00Outperform$0.0000.00% ROINUVBNuvation Bio9/8/2025Reiterated Rating$3.88$6.00Outperform$0.0000.00% ROINUVLNuvalent9/8/2025Reiterated Rating$80.89$115.00Outperform$0.0000.00% ROIXNCRXencor9/2/2025Reiterated Rating$8.55$26.00Outperform$00.0000.00% ROITLXTelix Pharmaceuticals8/28/2025Reiterated Rating$12.10$22.00Outperform$00.0000.00% ROIGBIOGeneration Bio8/13/2025Downgrade$4.05$7.00Neutral$0.0000.00% ROIXNCRXencor8/7/2025Lower Price Target$7.49$26.00Outperform$00.0000.00% ROIIMAImageneBio7/25/2025Lower Price Target$16.32$23.00Neutral$0.0000.00% ROIARGXargenex6/24/2025Reiterated Rating$550.14$715.00Outperform$000.0000.00% ROICATXPerspective Therapeutics6/23/2025Reiterated Rating$3.53$11.00Outperform$0.0000.00% ROIARGXargenex6/11/2025Reiterated Rating$575.46$715.00Outperform$000.0000.00% ROINUVBNuvation Bio6/11/2025Reiterated Rating$2.14$5.00Outperform$0.0000.00% ROITLXTelix Pharmaceuticals6/5/2025Initiated Coverage$17.48$22.00Outperform$0.0000.00% ROINTLAIntellia Therapeutics5/19/2025Reiterated Rating$9.09$10.00Neutral$00.0000.00% ROINUVBNuvation Bio5/15/2025Reiterated Rating$2.24$5.00Outperform$0.0000.00% ROINVCRNovoCure4/16/2025Lower Price Target$15.66$27.00Neutral$00.0000.00% ROIKNSAKiniksa Pharmaceuticals International4/16/2025Reiterated Rating$20.59$34.00Outperform$00.0000.00% ROIARGXargenex4/11/2025Reiterated Rating$577.38$715.00Outperform$000.0000.00% ROIIMNMImmunome3/20/2025Reiterated Rating$8.64$33.00Outperform$00.0000.00% ROISTROSutro Biopharma3/14/2025Downgrade$12.50$20.00Neutral$00.0000.00% ROIFATEFate Therapeutics3/6/2025Reiterated Rating$0.91$5.00Neutral$0.0000.00% ROIBCAXBicara Therapeutics2/6/2025Initiated Coverage$12.72$31.00Outperform$00.0000.00% ROIANABAnaptysBio2/3/2025Reiterated Rating$17.27$40.00Outperform$00.0000.00% ROIWATCH THIS BEFORE DECEMBER 8th!! (Ad)James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has noticed it. Altucher believes the filing could matter to as many as 1,806,000 Americans in the years ahead. He explains why Musk buried it and what it could mean, free of charge.Watch the free breakdown before December 8th to learn more Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital MarketsRaymond James Financial Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.